Compare INCY & FNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INCY | FNF |
|---|---|---|
| Founded | 1991 | 1847 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.0B |
| IPO Year | 1994 | 2005 |
| Metric | INCY | FNF |
|---|---|---|
| Price | $94.80 | $52.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 2 |
| Target Price | ★ $104.05 | $60.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | ★ 4173.33 | N/A |
| EPS | ★ 6.41 | 2.21 |
| Revenue | $3,394,635,000.00 | ★ $14,445,000,000.00 |
| Revenue This Year | $10.44 | $10.90 |
| Revenue Next Year | $10.99 | $5.44 |
| P/E Ratio | ★ $14.89 | $23.28 |
| Revenue Growth | ★ 13.67 | 5.58 |
| 52 Week Low | $57.77 | $42.78 |
| 52 Week High | $112.29 | $65.33 |
| Indicator | INCY | FNF |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 70.45 |
| Support Level | $93.54 | $50.82 |
| Resistance Level | $108.79 | $60.63 |
| Average True Range (ATR) | 2.36 | 1.14 |
| MACD | 0.07 | 0.70 |
| Stochastic Oscillator | 23.39 | 96.28 |
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Fidelity National Financial Inc is a provider of (i) title insurance, escrow and other title-related services, including trust activities, trustee sales guarantees, recordings and reconveyances and home warranty and (ii) transaction services to the real estate and mortgage industries. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. All of the company's revenue is generated in the United States.